Structure Therapeutics surges as oral GLP-1 shows 16.3% weight loss
Phase 2 trial results position aleniglipron against injectable leaders in expanding $73B market
Structure Therapeutics shares surged as much as 15% in premarket trading on Monday after the clinical-stage biotech reported what analysts described as potentially best-in-class weight loss results for its experimental oral obesity drug, positioning the company to compete with the market's dominant injectable treatments.
The South San Francisco-based company said its once-daily oral GLP-1 receptor agonist, aleniglipron, achieved a placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at 240 mg dose after 44 weeks in its Phase 2 ACCESS II trial, according to the company's press release. The results, equivalent to approximately 39 pounds of weight loss, showed no evidence of a plateau even at nearly a year of treatment.
"The totality of efficacy and tolerability data across the Phase 2 program continue to demonstrate clear differentiation of aleniglipron, with the highest weight loss observed for an oral GLP-1RA to date," said Raymond Stevens, Structure Therapeutics' chief executive officer. Stevens characterized the results as having "injectable-like efficacy that could become a backbone oral small molecule therapy for obesity."
The data places Structure Therapeutics in direct competition with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, injectable treatments that have dominated what J.P. Morgan projects will become a $200 billion incretin market by 2030. The global anti-obesity drug market is estimated at $8.65 billion in 2026 and forecast to reach $67.16 billion by 2034, growing at nearly 30% annually.
What sets aleniglipron apart is its oral formulation, which addresses a significant barrier to adoption for patients who avert needles. While Novo Nordisk launched an oral version of Wegovy in January, BMO Capital Markets analysts noted in a Monday research report that Structure Therapeutics' results "show what we believe to be a competitive profile vs. orforglipron and the Wegovy pill," adding that "even at the 180mg dose, efficacy looks to be highly competitive and better than orforglipron and the Wegovy pill."
The competitive advantage extends beyond convenience. As a small molecule, aleniglipron can be manufactured at scale with lower costs than peptide-based injectables, potentially enabling more accessible pricing. Stevens highlighted this manufacturing advantage in the company's statement, noting it could "facilitate efficient supply to the U.S. market."
The drug's safety profile appears manageable, with discontinuation rates due to adverse events ranging from 2% to 3.4% across studies—significantly lower than the up to 10.3% discontinuation rate observed with Eli Lilly's oral orforglipron and the 16.9% rate seen with Novo Nordisk's oral Wegovy in clinical trials. The most common side effects were gastrointestinal, primarily nausea and vomiting during the titration phase.
Structure Therapeutics plans to hold an end-of-Phase 2 meeting with the Food and Drug Administration in the second quarter of 2026 and intends to initiate Phase 3 trials in the second half of the year. That timeline puts the company behind competitors but potentially allows it to learn from their market experiences.
Analysts remain overwhelmingly bullish on the stock. Of 15 analysts covering Structure Therapeutics, all rate it a buy or strong buy, with an average price target of $108.93—nearly double Monday's closing price of $57.13. BMO Capital Markets maintained its Outperform rating with a $130 target price, while Guggenheim increased its target to $140.
The company's market capitalization stands at approximately $3.8 billion, with 96% of shares held by institutional investors. With no approved products yet on the market, Structure Therapeutics remains a high-risk, high-reward play on the obesity treatment boom.
Looking ahead, the company is also developing ACCG-2671, an oral amylin analog expected to enter clinical trials by the end of 2025. The drug could potentially be combined with aleniglipron for enhanced efficacy, addressing what Stevens called the company's goal of delivering "novel oral therapeutics to treat a range of chronic diseases with unmet medical needs."
With approximately 10 million Americans currently on GLP-1 treatments and J.P. Morgan projecting that number to reach 30 million by 2030, the market opportunity for an effective oral alternative remains substantial. Structure Therapeutics' Phase 2 results suggest it may have positioned itself to capture a meaningful share of that rapidly expanding market.